Ting Cheng: Why Gene Therapy Needs Reinvention Before It Can Reach Millions
Ting Cheng, Principal Scientist at Johnson & Johnson, AI/Tech and Pharma/Healthcare Investor, shared on LinkedIn:
”Pfizer approved a hemophilia gene therapy in 2025.
Then pulled it — because not a single patient ever received it after approval.
In that same seven-month window, five major pharma companies spent over $10 billion acquiring pre-commercial cell therapy companies, before any of them had treated a paying patient.
Both things are true at once, and the article breaks down what that actually means: the current generation’s manufacturing and pricing model is broken, not the underlying biology — which already has 34,000 treated patients and 14 billion USD in 2024 revenue behind five approved drugs.
The next wave is targeting something structurally different — a $150 billion market the current approach was never built to reach.
Read the full breakdown here.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C